Long-term outcomes of paediatric Guillain-Barré syndrome

Bastien Estublier1, Hélène Colineaux2,3, Catherine Arnaud2,3

  • 1Neuropediatric Department, Toulouse-Purpan University Hospital, Toulouse, France.

Insights

Two-thirds of children with Guillain-Barré syndrome (GBS) experience long-term sequelae, often minor but sometimes impacting daily life. Severe initial GBS and female sex predict worse outcomes.

Area of Science:

  • Pediatric Neurology
  • Neuromuscular Disorders
  • Clinical Pediatrics

Background:

  • Guillain-Barré syndrome (GBS) is an autoimmune disorder affecting the peripheral nervous system.
  • Long-term outcomes in pediatric GBS patients require further investigation.
  • Understanding sequelae is crucial for comprehensive patient management.

Purpose of the Study:

  • To investigate the prevalence and nature of long-term sequelae in children following GBS.
  • To identify factors associated with the development and severity of these sequelae.

Main Methods:

  • Prospective observational study conducted in two French tertiary centers.
  • Inclusion of 51 children diagnosed with GBS.
  • Data collection via clinical assessments and standardized scales/questionnaires over a median follow-up of 6 years and 4 months.

Main Results:

  • A 67% rate of long-term sequelae was observed, with most being minor (GBSDS=1).
  • Common complaints included paresthesia (43%), pain (35%), and fatigue (31%).
  • Initial GBS severity (GBSDS>4) and female sex predicted more severe late-onset conditions.

Conclusions:

  • Two-thirds of children with GBS experience persistent sequelae, often minor but with potential daily life repercussions.
  • Severe GBS during the acute phase is a significant predictor of worse long-term outcomes.
  • Early identification of risk factors is essential for targeted interventions in pediatric GBS.
Abstract

Related Concept Videos

Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
34
Long-term Potentiation01:35

Long-term Potentiation

Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
55.4K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.0K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K